Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is a risky bet given it's low Altman Z-score. Companies with a low Altman Z-score have a higher chance of going bankrupt within the next 2 years. The momentum for this stock is not very good. Madrigal Pharmaceuticals, Inc. is not a good growth stock. Madrigal Pharmaceuticals, Inc. is a good stock to invest in, but there are better stocks to choose.
Log in to see more information.
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therap...
MDGL Fundamental Data by TradingView

News

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Acquired by TD Asset Management Inc
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Acquired by TD Asset Management Inc

Ticker Report TD Asset Management Inc grew its position in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 10.7% during the second quarter, Holdings Channel reports. The firm owned 55,730 shares of...\n more…

Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to "Sell" by StockNews.com
Madrigal Pharmaceuticals (NASDAQ:MDGL) Upgraded to "Sell" by StockNews.com

Ticker Report StockNews.com upgraded shares of Madrigal Pharmaceuticals (NASDAQ:MDGL - Free Report) to a sell rating in a report released on Monday. Several other equities research analysts have also recently...\n more…

Short Report: Bearish positioning in Madrigal Pharmaceuticals at 3-month high
Short Report: Bearish positioning in Madrigal Pharmaceuticals at 3-month high

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $343.83 Consensus Target Price from Analysts
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives $343.83 Consensus Target Price from Analysts

Ticker Report Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the thirteen brokerages that are presently covering the firm...\n more…

Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?
Why Is Madrigal (MDGL) Up 1% Since Last Earnings Report?

Zacks Investment Research It has been about a month since the last earnings report for Madrigal (MDGL). Shares have added about 1% in that time frame, underperforming the S&P 500.Will the recent positive trend continue...\n more…

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zolmax Zurcher Kantonalbank Zurich Cantonalbank grew its stake in shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL - Free Report) by 18.8% in the second quarter, according to the company in its most...\n more…